Forte biosciences, inc. reports inducement grants under nasdaq listing rules

Dallas--(business wire)--forte biosciences, inc. (www.fortebiorx.com) (nasdaq: fbrx), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the nasdaq stock market rules. in accordance with nasdaq listing rule 5635(c)(4), the compensation committee of forte's board of directors approved the grant of equity awards to purchase a total of 70,000 shares of common stock to new non-exec.
NDAQ Ratings Summary
NDAQ Quant Ranking